Stresscopin (human)
Need Assistance?
  • US & Canada:
  • UK: +

Stresscopin (human)

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Stresscopin is a specific endogenous ligand of the corticotropin-releasing hormone receptor type 2 (CRHR2) that maintains homeostasis after stress. Intraperitoneal injection of stresscopin can inhibit the formation of heat induced edema in anesthetized rats. It also reduces food intake and inhibits gastric emptying activity.

Functional Peptides
Catalog number
CAS number
Molecular Formula
Molecular Weight
SCP (human); H-Thr-Lys-Phe-Thr-Leu-Ser-Leu-Asp-Val-Pro-Thr-Asn-Ile-Met-Asn-Leu-Leu-Phe-Asn-Ile-Ala-Lys-Ala-Lys-Asn-Leu-Arg-Ala-Gln-Ala-Ala-Ala-Asn-Ala-His-Leu-Met-Ala-Gln-Ile-NH2
White Powder
≥95% by HPLC
Store at -20°C
Soluble in Water
1. Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction
Allan Olson, Stephen J Greene, Cezar Macarie, Jerzy Korewicki, Lawrence I Deckelbaum, Serban-Ion Bubenek-Turconi, Ayan R Patel, Waldemar Radziszewski, Mihai Gheorghiade, Marco Metra, Orlando F Bueno, Piotr Ponikowski, Lilian Y Li, Jacek Grzybowski, Andreas Koester, Marvin A Konstam, Atalanta Ghosh, Aldo P Maggioni Eur J Heart Fail . 2013 Jun;15(6):679-89. doi: 10.1093/eurjhf/hft023.
Aims:Human stresscopin is a corticotropin-releasing factor (CRF) type 2 receptor (CRFR2) selective agonist and a member of the CRF peptide family. Stimulation of CRFR2 improves cardiac output and left ventricular ejection fraction (LVEF) in patients with stable heart failure (HF) with reduced LVEF. We examined the safety, pharmacokinetics, and effects on haemodynamics and serum biomarkers of intravenous human stresscopin acetate (JNJ-39588146) in patients with stable HF with LVEF ≤ 35% and cardiac index (CI) ≤ 2.5 L/min/m(2).Methods and results:Sixty-two patients with HF and LVEF ≤ 35% were instrumented with a pulmonary artery catheter and randomly assigned (ratio 3:1) to receive an intravenous infusion of JNJ-39588146 or placebo. The main study was an ascending dose study of three doses (5, 15, and 30 ng/kg/min) of study drug or placebo administered in sequential 1 h intervals (3 h total). Statistically significant increases in CI and reduction in systemic vascular resistance (SVR) were observed with both the 15 ng/kg/min (2 h time point) and 30 ng/kg/min (3 h time point) doses of JNJ-39588146 without significant changes in heart rate (HR) or systolic blood pressure (SBP). No statistically significant reductions in pulmonary capillary wedge pressure (PCWP) were seen with any dose tested in the primary analysis, although a trend towards reduction was seen.Conclusion:In HF patients with reduced LVEF and CI, ascending doses of JNJ-39588146 were associated with progressive increases in CI and reductions in SVR without significant effects on PCWP, HR, or SBP.Trial registration:NCT01120210.
2. Intracerebroventricular injection of stresscopin-related peptide enhances cardiovascular function in conscious rats
Ri-Long Piao, Ri Jin, Chun-Ping Chu, Hiroshi Kannan, De-Lai Qiu, Mei-Zi Li, Qing-Hua Jin, Yan-Hua Bing, Ying-Jun Li Regul Pept . 2013 Sep 10;186:7-11. doi: 10.1016/j.regpep.2013.07.001.
Stresscopin-related peptide (SRP), which is a member of the corticotropin-releasing factor (CRF) family, is a high-affinity ligand for the type 2 corticotropin-releasing factor receptor (CRF-R2) and is involved in stress-coping responses. Central treatment with SRP suppresses food intake, delays gastric emptying and decreases heat-induced edema, but the effects of central administration of SRP on the cardiovascular system are unclear. Here we examined the effects of intracerebroventricular (i.c.v.) administration of SRP on cardiovascular function, and compared the cardiovascular effects of SRP and stresscopin (SCP). Our results showed that i.c.v. administration of SRP (0.5nmol) increased mean arterial blood pressure (MABP) and heart rate (HR), but failed to increase plasma norepinephrine and epinephrine levels. Compared with an equivalent dose of SCP, the area under the curve (AUC) values for the changes in MABP and HR were significantly smaller with SRP, indicating that the cardiovascular effects of SRP were weaker than those mediated by SCP. Pre-treatment with a selective CRF-R2 antagonist, antisauvagine-30 (4nmol, i.c.v.) abolished the SRP and SCP induced changes in MABP and HR. These results indicate that central administration of SRP induces a weaker enhancement of cardiovascular function through CRF-R2 than that induced by SCP and that these effects are mediated without increasing plasma norepinephrine and epinephrine levels.
3. Suppression of progesterone production by stresscopin/urocortin 3 in cultured human granulosa-lutein cells
Nobuyuki Maruo, Ai Yata, Takeshi Maruo, Noriyuki Ohara, Koji Nakabayashi, Senn Wakahashi Hum Reprod . 2009 Jul;24(7):1748-53. doi: 10.1093/humrep/dep063.
Background:Corticotropin-releasing hormone (CRH) and its receptors have been identified in female reproductive tissues. CRH regulates follicular maturation, ovulation, luteolysis and steroidgenesis. A CRH-related peptide stresscopin (SCP), or urocortin III (Ucn3), has recently been identified, but its functions in the ovary remain to be elucidated. In the present study, we investigated the effects of SCP/Ucn3 on progesterone production in cultured human granulosa-lutein cells.Methods:The presence of SCP/Ucn3 and CRH type-2 receptor (CRHR2) in cultured granulosa-lutein cells from 21 infertile women (aged 22-36 years) was examined by RT-PCR and immunocytochemistry. The concentration of SCP/Ucn3 in follicular fluid, human serum and culture medium was examined by radioimmunoassay. Progesterone production by cultured granulosa-lutein cells treated with SCP/Ucn3 was examined by enzyme-linked immunosorbent assay.Results:SCP/Ucn3 and CRHR2 mRNAs and proteins were expressed in granulosa-lutein cells. SCP/Ucn3 was detected in culture media of granulosa-lutein cells and follicular fluid. Treatment of cultured granulosa-lutein cells with 0.1, 1.0 or 10 nM SCP/Ucn3 decreased progesterone secretion when compared with untreated control (all P < 0.05). Concomitant treatment with the CRHR2 antagonist antisauvagine-30 counteracted the inhibitory effects of SCP/Ucn3 on progesterone secretion, suggesting a mediatory role of CRHR2.Conclusions:The present results suggest that the SCP/CRHR2 system is present in human ovaries and treatment with SCP/Ucn3 inhibits progesterone production by cultured granulosa-lutein cells through interaction with CRHR2.
Online Inquiry
Verification code
Inquiry Basket